Soteropoulos Paula 4

What Happened Paula Soteropoulos, a director of Dianthus Therapeutics (DNTH), exercised stock options to acquire 27,594 shares at an exercise price of $8.44 per share (cost $232,893) and on the same day sold those 27,594 shares in an open-market transaction at $78.05 per share for total gross proceeds of $2,153,712. The filing also reports a related derivative disposition of 27,594 shares at $0.00. The transactions were executed on March 24, 2026 and reported on a Form 4 filed March 26, 2026.

Key Details

• Transaction date: 2026-03-24; Form 4 filed: 2026-03-26 (timely filing).
• Exercise: 27,594 shares exercised at $8.44 = $232,893 (code M, Acquired).
• Sale: 27,594 shares sold at $78.05 = $2,153,712 (code S, Disposed).
• Derivative line: 27,594 shares reported disposed at $0.00 (code M, likely related to the exercise/settlement mechanics).
• Reported under a Rule 10b5-1 trading plan adopted December 23, 2025 (Footnote F1).
• Vesting note: the option award vests 25% on April 6, 2023, then monthly over the next three years (Footnote F2).
• Shares owned after the transactions: not specified in the filing.

Context This was an option exercise combined with an immediate sale (commonly called a cashless exercise/sale). Gross sale proceeds were $2.15M; after subtracting the $232.9k exercise cost, the transaction generated roughly $1.92M in proceeds before taxes, fees, or any withholding. The sale was made pursuant to a pre-established 10b5-1 plan, which typically indicates the trades were automated according to a plan adopted before the sale date.